Français Néerlandais Japonais Chinois Allemand Espagnol Portugais

AstraZeneca ramps up investment in Dunkerque

04 Nov 2013 | Investment, Health Nutrition

AstraZeneca will invest €26 million in a new production line for the Symbicourt asthma inhaler at its Dunkerque plant. Existing lines will also be upgraded.

AstraZeneca -  pharmaceutical laboratory - Symbicort - health - Lille Region

            Present in Dunkerque for over 20 years, pharmaceutical giant AstraZeneca has invested some €500 million in its local plant to date—outlays that reflect the facility’s strategic importance as the world’s sole producer of Symbicort inhalers. With demand for the asthma remedy on the rise, the plant needed new capacity. “The aerosol technology we use for this inhaler is fairly unique within our group, and is concentrated at Dunkerque,” says Plant Manager Dominique Bretaudeau.

            The plant, which exports 95% of its total output to the United States, has a long tradition of meeting challenges and adapting to changing patient needs. In addition to special projects, it invests around €2.5 million a year to upgrade and maintain equipment, enhance patient safety and improve packaging.

            AstraZeneca is one of the world’s top pharmaceutical companies and ranks fifth in the field in France. Its medicines cover six main therapeutic areas: cardiovascular & metabolic, infection, gastrointestinal, oncology, neurosciences and respiratory ailments. Sales total around $28 billion, with over $4 million invested in R&D each year.

 

Source: AstraZeneca / Press

Back to news

News

Japanese company Takara Foods sets up business in Hauts-de-France

For its first location in Europe, Takara Foods, the Japanese agrifood company, has chosen Hauts-de-France!

New research facility for Kubota in Hauts-de-France

The Japanese company Kubota is investing in Hauts-de-France for the creation of its European R&D center. A hundred jobs will eventually be created there.

All news